Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.
Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.
